ALSO NOTED: Novartis licenses MedImmune vaccine IP; Rumor Mill: Dr. Reddy bids for Bradley; and much more...

> Rumor Mill: Generic drugmaker Dr. Reddy's Laboratories is said to have submitted a bid for U.S.-based Bradley Pharma. FiercePharma

> Novartis has licensed MedImmune's reverse genetics intellectual property. Novartis will use the IP to support development of vaccine strains for seasonal, pre-pandemic and pandemic influenza vaccines. Financial details of the deal were not disclosed. Release

> Precision Therapeutics, which makes tests to analyze tumor cells, is planning an $80.5 million IPO. Report

> Two Massachusetts General Hospital researchers describe a way of creating novel enzymes that, for the first time, do not require prior understanding of exactly how the enzymes work. FierceBioresearcher

> A group of neurologists have been studying the role a particular enzyme plays in creating memories, saying that blocking the enzyme could offer a new approach to treating post-traumatic stress disorders as well as chronic pain. FierceBioresearcher

And Finally... The FDA wants more detailed sunscreen labels. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.